ProCE Banner Activity

Immunotherapy in Stage III and Earlier Stage NSCLC: Optimizing Care Today and Tomorrow

Slideset Download
Download this slideset for expert perspectives on the optimal use of immune checkpoint inhibitors for stage III NSCLC in the clinic today, as well as a look at emerging approaches with these agents in this and earlier stages of disease.

Released: November 08, 2019

Expiration: November 06, 2020

No longer available for credit.

Share

Faculty

Roy S. Herbst

Roy S. Herbst, MD, PhD

Professor
Chief, Section of Thoracic Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
Department of Thoracic/Head and Neck Medical Oncology
Department of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Melissa L. Johnson

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Roy S. Herbst, MD, PhD

Professor
Chief, Section of Thoracic Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
Department of Thoracic/Head and Neck Medical Oncology
Department of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois